The American Journal of Medicine
Volume 122, Issue 10 , Pages 962.e1-962.e8 , October 2009

Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review

  • Samuel Abourbih

      Affiliations

    • Divisions of Cardiology and Clinical Epidemiology, Jewish General Hospital, Montreal, Quebec
    • Faculty of Medicine, McGill University, Montreal, Quebec
    • ,
  • Kristian B. Filion, MSc

      Affiliations

    • Divisions of Cardiology and Clinical Epidemiology, Jewish General Hospital, Montreal, Quebec
    • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec
    • Division of Clinical Epidemiology, McGill University Health Center, Montreal, Quebec
    • ,
  • Lawrence Joseph, PhD

      Affiliations

    • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec
    • Division of Clinical Epidemiology, McGill University Health Center, Montreal, Quebec
    • ,
  • Ernesto L. Schiffrin, MD, PhD

      Affiliations

    • Division of Internal Medicine, Jewish General Hospital, Montreal, Quebec
    • ,
  • Stephane Rinfret, MD, MSc

      Affiliations

    • Centre de Recherche de l'Hopital Laval, Quebec, Quebec
    • ,
  • Paul Poirier, MD, PhD

      Affiliations

    • Institut de Cardiologie et de Pneumologie, Hôpital Laval, Sainte-Foy, Quebec
    • ,
  • Louise Pilote, MD, MPH, PhD

      Affiliations

    • Division of Clinical Epidemiology, McGill University Health Center, Montreal, Quebec
    • Division of Internal Medicine, McGill University Health Center, Montreal, Quebec
    • ,
  • Jacques Genest, MD

      Affiliations

    • Division of Cardiology, Royal Victoria Hospital, Montreal, Quebec
    • ,
  • Mark J. Eisenberg, MD, MPH

      Affiliations

    • Divisions of Cardiology and Clinical Epidemiology, Jewish General Hospital, Montreal, Quebec
    • Faculty of Medicine, McGill University, Montreal, Quebec
    • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec
    • Corresponding Author InformationRequests for reprints should be addressed to Mark J. Eisenberg, MD, MPH, Professor of Medicine, Divisions of Cardiology and Clinical Epidemiology, Jewish General Hospital/McGill University, 3755 Côte Ste-Catherine Road, Suite A-118, Montreal, Quebec, Canada H3T 1E2

References 

  1. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement (Quality of reporting of meta-analyses). Lancet. 1999;354:1896–1900
  2. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–27
  3. Pauciullo P, Borgnino C, Paoletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis. 2000;150:429–436
  4. Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes (A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study). Diabetes Care. 1998;21:641–648
  5. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861
  6. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003;107:1733–1737
  7. Farnier M, Roth E, Gil-Extremera B, et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J. 2007;153:e1–e8
  8. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005;26:897–905
  9. Knopp RH, Brown WV, Dujovne CA, et al. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med. 1987;83:50–59
  10. Davidson MH, Bays HE, Stein E, et al. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006;29:268–273
  11. Krempf M, Rohmer V, Farnier M, et al. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia. Diabetes Metab. 2000;26:184–191
  12. Seidehamel RJ. Fenofibrate in type IV and type V hyperlipoproteinemia. Cardiology. 1989;76(Suppl 1):23–28
  13. Frick MH, Heinonen OP, Huttunen JK, et al. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease (An ancillary study in the Helsinki Heart Study frame population). Ann Med. 1993;25:41–45
  14. Vinik AI, Colwell JA. Effects of gemfibrozil on triglyceride levels in patients with NIDDM (Hyperlipidemia in Diabetes Investigators). Diabetes Care. 1993;16:37–44
  15. Schaefer EJ, Lamon-Fava S, Cole T, et al. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. Atherosclerosis. 1996;127:113–122
  16. Avogaro A, Piliego T, Catapano A, et al. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients (For the Gemfibrozil Study Group). Acta Diabetol. 1999;36:27–33
  17. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993;94:13–20
  18. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia (Safety of treatment, changes in risk factors, and incidence of coronary heart disease). New Engl J Med. 1987;317:1237–1245
  19. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol (Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group). N Engl J Med. 1999;341:410–418
  20. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  21. Zhou Z, Rahme E, Pilote L. Are statins created equal? (Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention). Am Heart J. 2006;151:273–281
  22. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med. 2000;247:563–569
  23. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585–2590
  24. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13:417–426
  25. Federman DG, Hussain F, Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J. 2001;94:1023–1026
  26. McClure DL, Valuck RJ, Glanz M, et al. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol. 2007;60:812–818
  27. Oldemeyer JB, Lund RJ, Koch M, et al. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology. 2000;94:127–128
  28. Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99:21i–33i
  29. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  30. Campos H, Genest JJ, Blijlevens E, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12:187–195
  31. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908–917
  32. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219
  33. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882–888
  34. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493–498
  35. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185–197
  36. Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005;165:725–730
  37. Allemann S, Diem P, Egger M, et al. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Curr Med Res Opin. 2006;22:617–623
  38. Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007;297:1362–1373
  39. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002;325:1139

 Funding: This work is supported by the Canadian Institutes of Health Research (MOP: 82918). Samuel Abourbih is supported by a McGill Faculty of Medicine Summer Research Bursary. Kristian Filion is supported, in part, by a bursary from the Fonds de la Recherche en Santé du Québec (FRSQ). Dr Joseph is a Scientist of the FRSQ. Dr Schiffrin holds a Canada Research Chair in Vascular and Hypertension Research. Drs Poirier and Rinfret are Junior Physician-Scientists of the FRSQ. Dr Pilote is a Physician-Scientist of the Canadian Institutes for Health Research. Dr Genest holds the McGill University/Novartis Chair in Medicine. Dr Eisenberg is a Chercheur-National of the FRSQ.

 Conflict of Interest: Jacques Genest has been on an advisory board for Sanofi-Aventis for the past 3 years and has received honoraria from Sanofi-Aventis. He does not own stock in the company. No other authors have declared any conflicts of interest.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)00490-2

doi: 10.1016/j.amjmed.2009.03.030

The American Journal of Medicine
Volume 122, Issue 10 , Pages 962.e1-962.e8 , October 2009

Article Tools

* Image Usage & Resolution